4 stories from 3 sources
Day’s Recap is unavailable for this topic and date. Feel free to go through our curated list of stories below.
A curated list of other prominent stories from this day.
A fast-growing black market for injectable peptides is expanding beyond weight loss into sleep and other wellness uses, riding demand created by GLP-1 popularity. Many products are not FDA tested, and misuse of self-injection adds safety risk on top of uncertain quality and dosing.
5:30 PMBloomberg MarketsFederal prosecutors charged a Texas physician with orchestrating an $89 million health care fraud scheme by billing insurers for medically unnecessary cardiovascular screening tests. The case centers on alleged overuse of high-reimbursement diagnostics presented as clinical need.
11:28 AMStat NewsResearchers found that H5N1 concentrates in cows' udders because the virus binds to receptors that are abundant in mammary tissue rather than in the lungs. The finding explains the unusual disease pattern in dairy herds and offers a clearer target for surveillance.
10:31 AMScienceDailyEli Lilly and the FDA granted a 79-year-old patient access to an experimental obesity drug through the FDA’s compassionate use pathway. The case involved unusually swift, exceptional access outside a clinical trial while the product remained unapproved.
4:30 AMStat NewsSummary
A fast-growing black market for injectable peptides is expanding beyond weight loss into sleep and other wellness uses, riding demand created by GLP-1 popularity. Many products are not FDA tested, and misuse of self-injection adds safety risk on top of uncertain quality and dosing.
Why it matters
The peptide boom is creating a large, hard-to-police safety and fraud exposure that could trigger regulatory crackdowns and reshape access to injectable wellness drugs.
Summary
Federal prosecutors charged a Texas physician with orchestrating an $89 million health care fraud scheme by billing insurers for medically unnecessary cardiovascular screening tests. The case centers on alleged overuse of high-reimbursement diagnostics presented as clinical need.
Why it matters
Aggressive fraud enforcement can quickly reshape what gets reimbursed, which providers get scrutinized, and how easily patients access high-cost diagnostics.
Summary
Researchers found that H5N1 concentrates in cows' udders because the virus binds to receptors that are abundant in mammary tissue rather than in the lungs. The finding explains the unusual disease pattern in dairy herds and offers a clearer target for surveillance.
Why it matters
Knowing where H5N1 replicates in cows improves surveillance and containment, reducing the chance that a farm outbreak becomes a wider human-health problem.
Summary
Eli Lilly and the FDA granted a 79-year-old patient access to an experimental obesity drug through the FDA’s compassionate use pathway. The case involved unusually swift, exceptional access outside a clinical trial while the product remained unapproved.
Why it matters
Compassionate use decisions can set de facto precedents for who gets scarce, unapproved obesity therapies and under what rules.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!